Smith & Nephew plc (SNN) Stock: Price, Forecast & Analyst Target
Smith & Nephew plc (SNN) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $29.83 (0.00%), as of the Nov 20, 2026 trading session; market cap $12.5B. Expected results Mar 1, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 16.58× (cash as of Jun 27, 2026) · expected results Mar 1, 2027
Smith & Nephew plc · SNN · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Smith & Nephew supplies healthcare providers with joint implants, trauma systems, arthroscopy equipment, ear, nose and throat solutions, and advanced wound products; it is a procedural medical-device platform, not merely a maker of replacement joints. Product launches must now offset competitive pressure in the United States while higher profit becomes dependable cash generation.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Smith & Nephew (SNN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Rising.
- quarterly revenue $3.10B (Q2 FY2026, quarter ended Jun 27, 2026)
- Altman Z 3.10 · Piotroski F 8
- ROE 11.9% · ROA 5.2% · current ratio 2.14
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 85 | Exceptional | |
| 85 | Exceptional | |
| 85 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $29.83 | |
| Change on the day | 0.00% | |
| 52-week range | $26.12–$37.09 | |
| Market capitalisation | $12.5B | — |
| Price / earnings (trailing) | 20.00 | |
| Shares traded on the day | 1.23M | |
| Beta (volatility vs the S&P 500) | 0.69 | |
| Dividends per share (last 12 months) | $0.79 | |
| Dividend yield (last 12 months) | 2.60% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Now taking into account revenue performance, we now expect underlying revenue growth of around 4% for 2026.
Deepak Nath · Statement from
We are seeing the impact of competitor launches in the U.S., but we expect growth to strengthen in the second half as we launch EVOS, Pelvic and ramp up TRIGEN MAX.
John Rogers · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Smith & Nephew (SNN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Smith & Nephew (SNN), and what does it report?
Short answer
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Research dated 2026-09-13.
Demand comes from procedures and wound treatment: healthcare providers buy implants and fracture-stabilization systems, instruments and visualization equipment for minimally invasive surgery, and products used across acute, chronic and postoperative wounds.
Reported sales place orthopaedics, sports medicine, and ear, nose and throat products in a combined category, with Advanced Wound Management reported separately. Most revenue comes from the combined category, so consolidated growth primarily reflects surgical devices even though wound care remains a meaningful business.
What do the latest results show for Smith & Nephew (SNN)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3.10B.
Research dated 2026-09-13.
Annual revenue and net income have advanced across recent reporting periods, and the latest comparable-period figures continued that pattern. Revenue rose, gross profit and operating profit increased, and net income edged higher, although revenue was below the immediately preceding period. Reported earnings have also cleared estimates lately after earlier misses.
Management attributes current pressure in the United States to competitor launches and expects EVOS, Pelvic, and TRIGEN MAX to strengthen growth as their rollouts progress. That is a management expectation rather than an explanation already established by the reported results.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $3.10B Jun 27, 2026
- Latest quarter · R&D
- $150.00M Jun 27, 2026
- Latest quarter · SG&A
- $1.60B Jun 27, 2026
- Latest quarter · FMP standardized operating result
- $448.00M Jun 27, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 27, 2026 | $3.10B | $150.00M | $1.60B | $448.00M |
| Dec 31, 2025 | $3.20B | $203.00M | $1.52B | $365.00M |
| Jun 30, 2025 | $2.96B | $143.00M | $1.52B | $429.00M |
| Dec 31, 2024 | $2.98B | $206.00M | $1.40B | $329.00M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.10B Aug 4, 2026
- Latest report · revenue estimate
- $3.46B Aug 4, 2026
- Latest report · revenue vs estimate
- Below estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $3.10B | $3.46B | $0.9460 | $0.9390 |
| Mar 2, 2026 | $3.20B | $2.77B | $1.1800 | $1.1600 |
| Aug 5, 2025 | $2.96B | $1.53B | $0.8580 | $0.7900 |
| Feb 25, 2025 | $2.98B | $2.96B | $0.9380 | $0.9200 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3.10B | $303M | $0.70 (diluted) |
| Q4 FY2025 | $3.20B | $332M | $0.76 (diluted) |
| Q2 FY2025 | $2.96B | $293M | $0.68 (diluted) |
| Q4 FY2024 | $2.98B | $198M | $0.46 (diluted) |
What are the financial strengths and risks for Smith & Nephew (SNN)?
Short answer
Cash and short-term investments were $754.00M at the Jun 27, 2026 balance-sheet date. Operating cash flow was $450.00M for the quarter ended Jun 27, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has stayed positive throughout the displayed series, and recent generation remained above capital spending. Cash and short-term investments have also recovered to the highest point in that series, while liquidity ratios and quality screens indicate a sound near-term financial footing.
Debt still substantially exceeds cash and investments, leaving Smith & Nephew dependent on continued cash conversion rather than balance-sheet cash alone. Competitive pressure that slows surgical-device growth, or weaker working-capital performance while restructuring costs rise, would reduce the cash available for debt service and distributions.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $450.00M Jun 27, 2026
- Previous quarter · operating cash flow
- $889.00M Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 27, 2026 | $450.00M | −$190.00M |
| Dec 31, 2025 | $889.00M | −$294.00M |
| Jun 30, 2025 | $396.00M | −$139.00M |
| Dec 31, 2024 | $749.00M | −$209.00M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Smith & Nephew (SNN)?
Short answer · as of
The next earnings report is expected on Mar 1, 2027.
Research dated 2026-09-13.
The scheduled earnings update needs to pair continued revenue expansion with evidence that EVOS, Pelvic, and TRIGEN MAX are gaining traction against competitor launches in the United States. Consensus estimates assume further sales and earnings growth, raising the importance of execution in the combined surgical-device portfolio.
Cash conversion deserves equal attention. Management expects profit growth and working-capital discipline to support free cash flow despite a temporary increase in restructuring costs; operating cash flow, capital spending, and the cash balance will show whether that bridge is holding. Recent broker downgrades add context to the execution test without determining its outcome.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We continue to expect free cash flow in 2026 of around $800 million, driven by profit growth and continued focus on working capital, offset by a modest temporary increase in restructuring costs.
John Rogers ·
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Smith & Nephew compare with its peers?
Short answer
Smith & Nephew's score ranks 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with a device maker concentrated on joint reconstruction, Smith & Nephew reaches further across the procedure: implants and trauma hardware sit alongside arthroscopy tools, visualization systems, tissue-resection equipment, and ear, nose and throat products. Advanced Wound Management adds exposure to wound dressings, bioactive products, negative-pressure therapy, and hydrosurgery.
That breadth can spread demand across surgical and wound-care settings, but the reporting structure combines several surgical franchises into a large category. Investors therefore see less divisional detail than the product range itself might suggest.
| Company | Price | Market value | Score |
|---|---|---|---|
| $156.59 Nov 19, 2026 | $15.9B | 95 5-pillar Nov 18, 2026 | |
| $68.60 Nov 19, 2026 | $9.09B | 94 5-pillar Nov 18, 2026 | |
| $610.54 Nov 20, 2026 | $17.1B | 92 5-pillar Nov 18, 2026 | |
| $319.12 Nov 20, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $63.78 Nov 20, 2026 | $31.6B | 91 5-pillar Nov 18, 2026 | |
| $254.76 Nov 19, 2026 | $24.7B | 87 5-pillar Nov 18, 2026 | |
| $133.17 Nov 20, 2026 | $9.24B | 85 5-pillar Nov 18, 2026 | |
| Smith & Nephew (SNN) — this page | $29.83 | $12.5B | 84 |
| $155.17 Nov 20, 2026 | $10.9B | 83 5-pillar Nov 18, 2026 | |
| $101.10 Nov 20, 2026 | $19.1B | 79 5-pillar Nov 18, 2026 | |
| $28.61 Nov 20, 2026 | $28.0B | 78 5-pillar Nov 18, 2026 | |
| $358.90 Nov 20, 2026 | $9.65B | 77 5-pillar Nov 18, 2026 | |
| $67.72 Nov 19, 2026 | $38.9B | 73 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $33.88 – $33.88
- Consensus target
- $33.88
- Median target
- $33.88
Consensus record · Captured .
Measured against a quoted price of $29.83 (as of Nov 20, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 8.1% Period end Sep 30, 2026
- Previous quarter · ownership
- 8.5% Prior to period end Sep 30, 2026
- Reporting holders
- 260 Period end Sep 30, 2026
- Previous quarter · holders
- 298 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Goldman Sachs Group INC | 4,204,122 |
| River Road Asset Management, LLC | 2,927,860 |
| Brandes Investment Partners, LP | 2,413,144 |
| Lmr Partners Llp | 2,246,567 |
| Morgan Stanley | 1,916,394 |
Tracked investors
Which of the 16 named investors we follow held SNN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SNN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Smith & Nephew (SNN)?
What Investors Ask About Smith & Nephew (SNN) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Smith & Nephew sell beyond hip and knee implants?
The portfolio includes trauma and extremities systems, arthroscopy instruments and visualization equipment, tissue-resection devices, ear, nose and throat solutions, wound dressings, bioactive products, negative-pressure therapy, and hydrosurgery systems.
Why do EVOS, Pelvic, and TRIGEN MAX matter to Smith & Nephew?
Management has tied these launches and product ramps to an expected improvement in United States growth after competitor launches pressured performance. Their commercial progress is therefore a direct test of the stated recovery mechanism.
How important is Advanced Wound Management to Smith & Nephew?
Advanced Wound Management is a substantial but smaller revenue stream than the combined orthopaedics, sports medicine, and ear, nose and throat category. It broadens the company beyond implants through wound care, bioactives, regenerative products, and treatment devices.
Can Smith & Nephew operating cash flow support its dividend and debt load?
Recent operating cash flow has covered capital spending, and distributions have continued, but debt remains well above cash and investments. Ongoing support therefore depends on sustained cash conversion, including the working-capital improvement management expects.
What is the SNN stock price today?
The last price recorded for Smith & Nephew plc (SNN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SNN price target?
The analyst consensus price target for Smith & Nephew plc (SNN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 84 figures on this page — 2 from SEC filings and earnings calls, 73 from Financial Modeling Prep (FMP), 3 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com